Background {#Sec1}
==========

Endocrine long-term complications are common in childhood cancer survivors \[[@CR1]--[@CR6]\]. After cranial radiotherapy (cRT), multiple endocrine functions can be affected \[[@CR7], [@CR8]\]. In a large retrospective study with a cohort of 748 childhood cancer survivors treated with cRT, the estimated point prevalence for growth hormone (GH) deficiency was 46.5%, 10.8% for thyroid-stimulating (TSH) hormone deficiency and 4% for adrenocorticotropic hormone deficiency (ACTH) \[[@CR9]\], respectively. As young age at the time of radiation represents a risk factor for the development of endocrine deficiencies after cRT \[[@CR10]\], the prevalence of cRT-induced hypothalamic-pituitary (HP) axis-related sequelae in adult patients may vary.

In contrast to comprehensive data on childhood cancer patients, information on hormonal impairment after cRT in adults is scarce. Reviewing eighteen studies with a total of 813 adult cancer patients treated with cRT (nasopharyngeal cancer and non-pituitary brain tumors) in 2011, Appelman-Dijkstra et al. were able to show that the prevalence of cRT-induced hypopituitarism was of clinical relevance and argued for a structured periodical endocrine follow-up of these adults \[[@CR11]\].

We aimed to update the existing knowledge database on HP axis dysfunction after cRT in adult cancer patients (non-pituitary brain tumors and nasopharyngeal cancer) by including current literature for further debate. We were able to gather more detailed information on the course of HP axis impairment after WBRT in adults, enabling the discussion of the following clinical questions in particular: i) What is the current evidence on HP axis dysfunction after WBRT in literature? ii) Are WBRT doses within the range of potential harm? iii) Can we neglect the impact of cRT-related hormonal deficiency in patients with brain metastases and limited life expectancy as a typically late manifesting side effect?

Methods {#Sec2}
=======

On April 25th, 2019 the PubMed database and the Cochrane library were searched for the following terms: "cranial radiotherapy" OR "cranial irradiation" AND "hypopituitarism" OR "pituitary deficiency" OR "hormonal changes" OR "hormonal impairment" OR "hormonal deficiency". Only studies written in English on adult cancer patients (≥18 years, non-pituitary brain tumors, head and neck cancers and brain metastases) with information on endocrine function after cRT were considered. The initial search was supplemented with manual searches of the reference lists and cross-referencing. A PRISMA flow chart \[[@CR12]\] summarizes the selection process (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1PRISMA flow chart summarizing the selection process

Results {#Sec3}
=======

The initial search returned 889 citations, with 286 remaining after removing duplicates and limiting the results to adult cancer patients (Fig. [1](#Fig1){ref-type="fig"}). After screening titles and abstracts, 28 original full papers with a total of 1728 patients were included.

Search results could mainly be assigned to the tumor entities nasopharynx carcinoma/ skull base tumors (15 studies) and non-pituitary brain tumors (13 studies). No study with a focus on endocrine assessment after WBRT in adult cancer patients was found.

The overall prevalence of pituitary dysfunction ranged from 20 to 93% (GH: 19--100%, ACTH: 4--73%, TSH: 4--70%, LH/FSH: 0--55%, PRL: 7--100%). The time interval from cRT to endocrine assessment ranged from 3 months to 25.6 years. In 13 studies, the median start of follow-up exceeded three years. The total radiation dose to the pituitary gland/hypothalamus ranged from 4 to 97 Gy. Eight studies did not supply estimated doses to the HP axis. Table [1](#Tab1){ref-type="table"} summarizes the search results. Table 1Studies with data on pituitary hormonal impairment after cranial radiotherapy in adult cancer patientsAuthorPatientsAge (years)Tumor\
entityRT dose\
(Gy)Time since RTPituitary hormonal impairment (axis)Any deficiencyGH deficiencyACTH\
deficiencyTSH\
deficiencyLH/FSH deficiencyPRL (hyperprolactinemia)Lamba 2019\[[@CR13]\]74NRMeningeomaNRFollow up: mean: 43 monthsMean time to develop hormone deficiency: 11--32 months19% (14/74)24% (18/74)24% (18/74)10% (7/74)NRHandisurya 2018(prospective)\[[@CR14]\]43652 (19--83)Brain54--60 GyNo statement on dose to the pituitary/hypothalamusBaseline3 months after RT6 months after RT1 years after RT2 years after RT3 years after RT\> 3 years after RTNRNR21%16.8%11.3%10.2%1.4%5.7%10.9%0% / 0%\*7.1% / 0%\*32.7% / 0%\*35.3% / 0%\*41.7% / 0%\*52.2% / 0%\*24% / 0%\*LH: always 0%20% / 11%\*2% / 18.8%\*1.3% / 6.8%\*3.1% / 10.3%\*22.2% / 0%\*55.6% / 4.3%\*26% / 42.1%\*Kyriakakis 2016\[[@CR15]\]10740 ± 13.1Brain54Gy, estimated dose to the HP axis 35.9 ± 15.5Gy\*\*8 years 5.3--11 years88%86.9%23.4%11.2%34.6%15%Ipekci 2014\[[@CR16]\]3045.2 ± 9.8NasopharyngealMean dose to the pituitary: 46Gy (23--66)Mean dose to the hypothalamus: 10Gy (4--41)10--133 months93% (28/30)77% (23/30)73% (22/30)27% (8/30)NR43% (13/30)Ratnasingam 2014 \[[@CR17]\]5057 ± 12.2NasopharyngealNo statement on dose to the pituitary/hypothalamusMedian: 8 years (3--21)82% (41/50)78% (39/50)40% (20/50)4% (4/50)22% (11/50)30% (15/50)Seland 2014 \[[@CR18]\]14042.5 (15--76)Head and neckPituitary: 13Gy (0--68)16 years (5--29)73% (102/140)25% (32/140)34% (45/140)34% (45/140)55%NRAppelman-Dijstra 2014\[[@CR19]\]8047.5 (18.6--89.7)BrainPituitary: 56.27 (40--70)2 years after RT5 years after RT10 years after RT15 years after RT21% (17/80)47% (23/49)60% (27/45)89% (31/35)33% (27/80)31% (25/80)14% (11/80)25% (20/80)21% (17/80)Madischi 2011 \[[@CR20]\]2638.5 (33--47)BrainMean dose to the pituitary and hypothalamus: 41.8 Gy (30.7--49.8)\< 32 months (median: 27 months)38% (10/26)29% (7/26)22% (6/26)14% (4/26)4% (1/26)NRSnyders 2009\[[@CR21]\]76, 21 with endocrine evaluation56 (28--74)Sinunasal44-66Gy, estimated dose to the pituitary: 51--56, estimated dose to the hypothalamus: 44-52Gy107 months (11--253)62% (13/21)24% (5/21)19% (4/21)14% (3/21)19% (4/21)10% (2/21)Bhadare 2008 \[[@CR22]\]312, 112 with endocrine evaluationNRNasopharyngeal40-70Gy63 months (6--365)60% (67/112)36% (16/44)32% (14/44)70% (31/44)27% (12/44)15% (10/68)Schneider 2006 \[[@CR23]\]68, 44 with endocrine evaluation20--79BrainNRNR38%(17/44)28%(12/44)19%(8/44)18%(7/44)29.5%(13/44)7%(3/44)Agha 2005 \[[@CR24]\]5639.3 ± 11.9BrainEstimated dose to the pituitary: 54Gy (4--97)6 years41% (23/56)32%(18/56)21%(12/56)9%(5/56)27%(15/56)32%(18/56)Johannesen 2003\[[@CR25]\]33,25 with endocrine evaluation38 (14--68)Brain54 Gy (45--59)13.1 years (6--25.6)64% (16/25)NR4%(1/25)56%(14/25)16%(4/25)0%(0/25)Popovic 2002 \[[@CR26]\]226 \> 18yNRBrain56 Gy, estimated dose to the pituitary: 25-30Gy7.6 ± 0.7 years (2--3)67%(4/6)67%(4/6)NRNRNRNRPai 2001 \[[@CR27]\]10741.2 (17--75)Chordoma/ chondrosarcomaEstimated dose to pituitary and hypothalamus: \< 50-70Gy5.5 years87%NR19%30%29%72%Arlt 1997\[[@CR28]\]3126--66BrainMean dose pituitary: 51.1Gy (±12.1) mean dose hypothalamus: 57Gy (±7.8)1.5--11 years77% (24/31)NR29% (9/31)Taphoorn 1995 \[[@CR29]\]1324--66Brain45--61 Gy, mean pituitary dose: 36.1 Gy (0--50)3 years (1--11.5)77%(10/13)31%(4/13)62%(8/13)0%(0/13)15%(2/13)23%(3/13)Constine 1993 \[[@CR30]\]326--65Brain39.6--70.2Gy2--13 years91% (28/32)NRNRNRNRNRLam 1991 \[[@CR31]\]2043.7 ± 8.4 (male)36.8 ± 9 (female)NasopharyngealEstimated dose to the pituitary 62Gy, estimated dose to the hypothalamus: 40Gy60 months75% (15/20)55% (11/20)25% (5/20)15% (3/20)35% (7/20)30% (6/20)Woo 1988 \[[@CR32]\]1133--64NasopharyngealEstimated dose to pituitary 62-67Gy, estimated dose to the hypothalamus: 41-45Gy72--240 months82% (9/11)90% (9/10)18% (2/11)45% (5/11)55% (6/11)27% (3/11)Samaan 1987 \[[@CR33]\]16647 (6--80)Nasopharyngealand paranasal sinusEstimated dose to the pituitary: 57 (4--75), estimated dose to the hypothalamus: 50 (11--75)12--312 months75% (124/166)75% (124/166)18% (30/166)20% (33/166)20% LH (33/166)35% FSH (58/166)36% (60/166)Lam 1987 \[[@CR34]\]3227--50Nasopharyngeal46--6060--204 months25% (8/32)19% (6/32)6% (2/32)13% (4/32)16% (5/32)19% (6/32)Mechanik 1986 \[[@CR35]\]1522--59Brain40--50 to whole brain2--9 years93%(14/15)NRNR14.3%(1/7)NR100%(9/9)Lam 1986 \[[@CR36]\]827--52Nasopharyngeal46--61, estimated to the pituitary 55--67\> 60 months100% (8/8)100% (8/8)50% (4/8)50% (4/8)25% (2/8)88% (7/8)Huang 1979(prospective) \[[@CR37]\]3716--65Nasopharyngealestimated dose to pituitary/hypothalamus: 46--56 GyBefore RT6 months after RT1 years after RT2 years after RTNR8.1%18.9%18.9%21.6%NS46%73%83.8%83.8%p = \< 0.010%21.6%27%37.8%p = \< 0.0110.8% / 48.6%56.8% / 83.8%51.4% / 83.8%56.8% / 81.1%(LH/FSH)*p* \< 0.01NRHarrop 1976 \[[@CR38]\]178 \< 18y8 \< 18Brain40--526 years (1--15)62.5%(5/8)50%(4/8)12.5%(1/8)12.5%(1/8)37.5%(3/8)NRRosenthal 1976 \[[@CR39]\]635--66Nasopharyngeal55--6512--96 months67% (4/6)100% (2/2)50% (1/2)67% (4/6)NRNRSamaan 1975 \[[@CR40]\]1026--55NasopharyngealEstimated dose to pituitary: 50--8360--240 months100% (10/10)60% (6/10)50% (5/10)40% (4/10)30% (3/10)50% (5/10)Abbreviations: *GH* growth hormone, *ACTH* adrenocorticotropic hormone, *TSH* thyroid-stimulating hormone, *LH* luteinizing hormone, *FSH* follicle-stimulating hormone, *PRL* prolactin, *Gy* Gray, *RT* radiation therapy, *NR* Not reported; \* younger and older than 50 years, \*\* subgroup analysis of the study group (Kyriakakis et al.)

Discussion {#Sec4}
==========

The review of 28 original articles showed that hypopituitarism occurs frequently in adult patients after cRT for nasopharyngeal cancer and non-pituitary brain tumors. The fact that not a single article was focused on hypopituitarism after WBRT in particular highlights the general need for our review of HP axis deficiencies after cRT to improve extrapolation of the results for WBRT patients.

In 2011, Appelman-Dijkstra et al. published a review and meta-analysis on pituitary dysfunction in adult patients after cRT including 18 studies with a total of 813 patients \[[@CR11]\]. The authors found hypopituitarism prevalent and concluded that all patients treated with cRT should undergo structured periodical assessment of pituitary functions \[[@CR11]\]. In the meantime, ten additional articles published including 915 new patients, justifying an update of the pre-existing database regarding the current literature. Our analysis additionally contributes to the debate of whether the onset of pituitary dysfunction and radiation dose leading to pituitary dysfunction could be of relevance for patients treated with WBRT.

Manifestation of cRT-induced endocrine deficiencies - potential relevance for patients with brain metastases and limited life expectancy? {#Sec5}
-----------------------------------------------------------------------------------------------------------------------------------------

Brain metastases are the most common brain tumors in adults, occurring in approximately 10--30% of adult cancer patients \[[@CR41]\]. While WBRT remains a primary treatment modality for many patients with high intracranial tumor burden, there has been a paradigm shift from WBRT to stereotactic small volume high precision RT (stereotactic surgery (SRS)) in patients with a limited number a brain metastases. However, there is no general consensus defining the cut-off for the number of lesions. Randomized studies support the use of SRS in 1--3 lesions \[[@CR42]--[@CR44]\] or up to 10 metastases \[[@CR45]\]. Still, WBRT (preferably with hippocampal sparing technique) remains an option for patients with more than a "limited number" of brain metastases.

In general, life expectancy of patients with brain metastases is limited \[[@CR41]\]. Recursive partioning analysis (RPA) of prognostic factors in Radiation Treatment Oncology Group (RTOG) brain metastases trials suggested three prognostic classes with median survival rates from 2.3 months to 7.1 months \[[@CR46]\]. More recently published prognostic scores, not only based on performance status and age, showed a more differentiated range of life expectancies in patients with brain metastases \[[@CR47]--[@CR49]\]. According to the scoring system established by Rades et al., the group with the best prognosis showed a 1-year survival rate of 49% \[[@CR48]\]. With the disease specific Graded Prognostic Assessment (GPA) score introduced by Spertudo et al., median survival of up to 18.7 months can be reached depending on the primary tumor site \[[@CR47]\].

All together, there are subgroups of patients with brain metastases that live significantly longer than the average. Apart from patients presenting with brain metastases, a prophylactic brain irradiation (PCI) was shown to be beneficial in patients with small cell lung cancer (SCLC) without evidence of intracranial disease \[[@CR50], [@CR51]\]. In cases of limited disease and complete remission after chemotherapy, survival rates sum up to approximately 60 and 35% after 1-year and 2-years, respectively \[[@CR50]\].

While the mean time to follow-up was longer than two years in the majority of analyzed studies, most studies also showed that hypopituitarism can already occur in the first year after treatment \[[@CR13], [@CR14], [@CR16], [@CR19]--[@CR22], [@CR29], [@CR31], [@CR33], [@CR37]\]. In particular, Lamba et al. reported all hormonal deficiencies in their study after a mean time of 11--32 months \[[@CR13]\]. All hypothalamic-pituitary insufficiencies occurred within 32 months after cRT in the study of Madaschi et al. \[[@CR20]\]. Handisurya et al. showed in their longitudinal study that low levels of thyroid and sexual hormones occur in a significant proportion of patients within the first months after initiation of therapy \[[@CR14]\]. The authors assumed that early hormonal impairment might be a coping mechanism of the body that contributes to the increased fatigue and weakness reported by many patients during or after cRT. While this toxicity is mostly interpreted as acute toxicity of cRT and/or side effect of steroid medication (used for symptomatic treatment of vasogenic edema), it is plausible that hormonal deficiencies, especially of anabolic hormones, and the lack of sexual functioning might contribute to an acute illness syndrome in this period \[[@CR52]\]. The incidence of hormonal deficiencies within six months after treatment start has not yet been reported and a potential benefit of hormonal replacement therapies has not yet been studied, as most studies started their endocrine follow-up in the second year after cRT or later \[[@CR14]\].

Are doses being used for WBRT within the range of potential harm to the HP axis? {#Sec6}
--------------------------------------------------------------------------------

Multiple dose regimes are common for WBRT ranging from 5 × 4 = 20 Gy, 10 × 3 = 30 Gy, 15 × 2.5 = 37.5 Gy and 20 × 2 = 40 Gy \[[@CR53]--[@CR56]\]. As the irradiated volume encompasses the entire cerebrum, the HP axis is always being treated with the total description dose. Several studies showed a dose-dependent effect on the development of hypopituitarism \[[@CR10], [@CR13], [@CR22], [@CR24], [@CR56], [@CR57]\]. So far, however, no threshold dose for hormonal impairment has been established. In the studies reviewed, doses to the pituitary and the hypothalamus ranged between 4 and 97 Gy. In half of the studies, a minimum dose to the HP area of less than 40 Gy was mentioned. Kyriakakis et al. suggested a threshold dose above 30 Gy to the HP area for long term endocrine surveillance \[[@CR56]\]. This is thoroughly within the dose range of a WBRT.

The vast majority of patients in the analyzed studies was treated with conventionally fractionated RT (1.8--2.0 Gy per fraction). In case of WBRT, a hypo-fractionated regime is often used (e.g. 10 × 3 = 30 Gy). Assuming an α/ß ratio of 3 for normal brain tissue, this biologically equals significantly higher doses. The lower the dose per fraction, the greater the sparing of late-reaction tissue \[[@CR58]\]. The HP axis behaves as a late-reacting tissue. A dose per fraction of more than 2 Gy administered over a shorter time period has a more severe effect on late-reacting tissues such as myelinated neurons and blood vessels \[[@CR7], [@CR59]\]. More profound cRT-induced hypopituitarism has been demonstrated with a dose per fraction greater than 2 Gy in older series \[[@CR60]\]. So far, however, no direct comparative data exists clearly supporting this hypothesis.

Moreover, modern cancer treatment approaches like immunotherapy carry the risk of additional autoimmune hypophysitis \[[@CR61]\]. To the best of our knowledge, no data exists on a synergistic risk of HP axis impairment with cRT and immunotherapy. In expectation of a more frequent use of immunotherapy, this topic might become of importance in the future.

Certain limitations might limit the scope of our analysis: Data on onset of hypopituitarism and estimated dose to the HP area were not completely reported by all included studies. For instance, eight studies did not supply estimated doses to the HP axis at all. The time interval from cRT to assessment of endocrine deficiencies was often documented as a range. In those cases, it is not known, how many patients developed a deficiency within the first two years and how many patients after a longer follow-up period. These ranges were included in our overview (Table [1](#Tab1){ref-type="table"}). Moreover, our analysis revealed a large variability in the prevalence of pituitary dysfunction (range 20--93%) and the total radiation dose to the HP axis (range 4--97 Gy) complicating interpretation. In addition, endocrine function testing varied substantially in the included studies. Also, as described by Merchant et al. in pediatric patients, pre-irradiation endocrinopathies might lead to a potential overestimation of the incidence of radiation-induced endocrinopathy \[[@CR62]\].

In lack of sufficient data, our conclusions were drawn from subpopulations, retrospective and heterogenous patient groups. Thus, while our hypotheses fall short of translating into patient care strategies, it clearly demonstrates the current need for future studies regarding dose constraints in order to improve care delivery, such as a sparing approach in WBRT and/or endocrine follow-up. Such trials should especially emphasize on rigorous data acquisition including relevant dose constraints to the HP axis so that ongoing prospective efforts can better address these issues.

Nonetheless, we believe that the extrapolation of published data on hypopituitarism in adult cancer patients with nasopharyngeal cancer and brain tumors should suffice to justify early routine endocrinological follow-up (within the first year after cRT) for patients with brain metastases and a favorable prognosis receiving WBRT or in patients with SCLC in need for a PCI. In order to prevent hypopituitarism after WBRT, a sparing approach of the HP axis might be an option and appears technically feasible (unpublished data of our study group).

Conclusion {#Sec7}
==========

Hypopituitarism after cRT in adult cancer patients occurs frequently, is dose dependent and can evolve within the first year after RT. A search of the current literature returned no data on hypopituitarism after WBRT in particular. Especially when treating a subgroup of patients with a favorable prognosis with WBRT one should consider the presented follow-up data from patients receiving cRT of nasopharyngeal cancer and brain tumors, as hypopituitarism has been described to occur within the dose range of WBRT (20--40 Gy) without a dose threshold. On the basis of the current literature, our debate further highlights the need for endocrinological evaluation following cRT and should encourage the initiation of further studies regarding a sparing approach of the HP area during WBRT.
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